
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
An app for birth control education, another that helps young patients transition to adult providers, and 3 more must-have adolescent apps for primary care.






